| Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes (NCT01536600) | Novo Nordisk A/S | 2004-09-01 |
| A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (NCT01571661) | GlaxoSmithKline | 2004-09-01 |
| Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes (NCT01542463) | Novo Nordisk A/S | 2004-09-01 |
| ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR) (NCT00229684) | AstraZeneca | 2004-09-01 |
| An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024) (NCT00094770) | Merck Sharp & Dohme LLC | 2004-09-01 |
| Insulin Glargine in Type 2 Diabetes (NCT00268645) | Sanofi | 2004-09-01 |
| A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes (NCT00144144) | Advanced-J | 2004-09-01 |
| An Online System to Improve Diabetes Self-Care (NCT00119938) | Robert Wood Johnson Foundation | 2004-09-01 |
| MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics) (NCT00157729) | Medicure | 2004-08-01 |
| Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin (NCT00135096) | Sanofi | 2004-08-01 |
| GALLANT 5 Tesaglitazar Versus Metformin (NCT00214591) | AstraZeneca | 2004-08-01 |
| In-Home Weight Loss Program for Adults With Type 2 Diabetes Delivered by Interactive Cable Television Technology (NCT00277277) | Bastyr University | 2004-08-01 |
| Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes (NCT00097279) | Novo Nordisk A/S | 2004-08-01 |
| An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice (NCT01498900) | Novo Nordisk A/S | 2004-08-01 |
| Effects of Chromium Supplementation on Parameters of the Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus (NCT00145093) | Medical Research Foundation, The Netherlands | 2004-08-01 |
| GALLANT 6 Tesaglitazar vs. Pioglitazone (NCT00214565) | AstraZeneca | 2004-08-01 |
| Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus (NCT00135083) | Sanofi | 2004-08-01 |
| MK0916 in Patients With Type 2 Diabetes and Metabolic Syndrome (0916-005) (NCT00543595) | Merck Sharp & Dohme LLC | 2004-08-01 |
| Experimental Studies of the Effects of Caffeine on Glucose Regulation (NCT00432887) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 2004-07-01 |
| Problem Solving and Cardiovascular Disease Risk Management in Diabetic Blacks (NCT00201110) | Johns Hopkins University | 2004-07-01 |
| Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes (NCT00593255) | Novo Nordisk A/S | 2004-07-01 |
| A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes (NCT00351585) | Novartis | 2004-07-01 |
| NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes (NCT00095446) | Novo Nordisk A/S | 2004-07-01 |
| Effects of Fats on Blood Glucose in People With and Without Type 2 Diabetes Mellitus (NCT00308373) | Mayo Clinic | 2004-07-01 |
| Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1) (NCT00108225) | US Department of Veterans Affairs | 2004-07-01 |
| A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes (NCT00238498) | Novartis | 2004-07-01 |
| Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11% (NCT00138593) | Novartis | 2004-07-01 |
| OPAL - Insulin Glulisine, Diabetes Mellitus (NCT00272012) | Sanofi | 2004-07-01 |
| Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes (NCT00564668) | Novo Nordisk A/S | 2004-06-19 |
| Observational Study to Evaluate the Safety of Levemir® in Diabetes (NCT00659295) | Novo Nordisk A/S | 2004-06-01 |
| Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021) (NCT00087516) | Merck Sharp & Dohme LLC | 2004-06-01 |
| Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus (NCT00086502) | Merck Sharp & Dohme LLC | 2004-06-01 |
| An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010 (NCT01294553) | GlaxoSmithKline | 2004-06-01 |
| Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes (NCT00624364) | Novo Nordisk A/S | 2004-05-01 |
| Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes (NCT00099944) | Novartis Pharmaceuticals | 2004-05-01 |
| Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes (NCT00099853) | Novartis Pharmaceuticals | 2004-05-01 |
| Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes (NCT00094991) | Bristol-Myers Squibb | 2004-05-01 |
| Effect of Thiazolidinedione Treatment Vascular Risk Markers (NCT00571506) | University of Arkansas | 2004-05-01 |
| Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes (NCT00099931) | Novartis Pharmaceuticals | 2004-05-01 |
| Enhancing Adherence in Type 2 Diabetes: The ENHANCE Study (NCT00222846) | University of Pittsburgh | 2004-05-01 |
| Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes (NCT00099918) | Novartis Pharmaceuticals | 2004-05-01 |
| DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines (NCT00233649) | AstraZeneca | 2004-05-01 |
| Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes (NCT00099892) | Novartis Pharmaceuticals | 2004-05-01 |
| Mode of Action of Topiramate in the Treatment of Obese Patients With and Without Type 2 Diabetes Mellitus (NCT00304603) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-04-01 |
| Comparing Pre-Mixed Insulin With Insulin Glargine Combined With Rapid-Acting Insulin in Patients With Type 2 Diabetes (NCT00110370) | Eli Lilly and Company | 2004-04-01 |
| Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty (NCT00162357) | Lantheus Medical Imaging | 2004-04-01 |
| Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes (NCT00553020) | Sanofi | 2004-04-01 |
| Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes (NCT00592527) | Novo Nordisk A/S | 2004-04-01 |
| The Effectiveness of Diabetes Patient Education and Self-Management Education in Persons With Type 2 Diabetes (NCT00906919) | University of Victoria | 2004-04-01 |
| Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin (NCT00135057) | Sanofi | 2004-04-01 |
| A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes (NCT00099905) | Novartis Pharmaceuticals | 2004-04-01 |
| Observational Study With InnoLet® in Daily Clinical Practice (NCT01492959) | Novo Nordisk A/S | 2004-03-23 |
| Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction (NCT01492218) | Novo Nordisk A/S | 2004-03-15 |
| Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises (NCT00753142) | Emory University | 2004-03-01 |
| Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11% (NCT00101673) | Novartis Pharmaceuticals | 2004-03-01 |
| Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes (NCT00600366) | Novo Nordisk A/S | 2004-03-01 |
| Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients (NCT00290394) | Baskent University | 2004-03-01 |
| Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone (NCT00095030) | Bristol-Myers Squibb | 2004-02-01 |
| Near Normalisation of BG Improves the Potentiating Effect of GLP-1 (NCT00612625) | Hvidovre University Hospital | 2004-02-01 |
| A Study on Efficacy and Safety of Topiramate OROS Controlled-Release in Obese, Type 2 Diabetic Subjects Managed With Diet or Metformin (NCT00231647) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-02-01 |
| Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes (NCT01497600) | Novo Nordisk A/S | 2004-02-01 |
| Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes (NCT00600626) | Novo Nordisk A/S | 2004-01-01 |
| Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes Mellitus (NCT01542060) | Novo Nordisk A/S | 2004-01-01 |
| Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes (NCT00099866) | Novartis Pharmaceuticals | 2004-01-01 |
| Exercise and Acarbose in Type 2 Diabetes (NCT01244971) | Karolinska Institutet | 2004-01-01 |
| Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes (NCT00568074) | Novo Nordisk A/S | 2003-12-16 |
| Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes (NCT00592969) | Novo Nordisk A/S | 2003-12-03 |
| Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes (NCT00605020) | Novo Nordisk A/S | 2003-12-02 |
| Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus (NCT00290927) | Sanofi | 2003-12-01 |
| Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes (NCT00619697) | Novo Nordisk A/S | 2003-12-01 |
| Paediatric Subjects - Special Survey (NCT01538576) | Novo Nordisk A/S | 2003-12-01 |
| Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes (NCT00605111) | Novo Nordisk A/S | 2003-12-01 |
| Special Survey for Patients With Type 1 or Type 2 Diabetes (NCT01538589) | Novo Nordisk A/S | 2003-12-01 |
| Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes (NCT01615978) | Novo Nordisk A/S | 2003-12-01 |
| Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone (NCT00604253) | Novo Nordisk A/S | 2003-12-01 |
| Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes (NCT00191464) | Eli Lilly and Company | 2003-12-01 |
| Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus (NCT01045590) | GlaxoSmithKline | 2003-12-01 |
| The Gene Expression Patterns in the Peripheral White Blood Cells of Type 2 Diabetic Patients (NCT00155922) | National Taiwan University Hospital | 2003-11-01 |
| Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin (NCT00082407) | AstraZeneca | 2003-11-01 |
| Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes (NCT00280046) | Novo Nordisk A/S | 2003-11-01 |
| A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM (NCT00308451) | Nutrition 21, Inc. | 2003-11-01 |
| A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics (NCT00067951) | GlaxoSmithKline | 2003-10-17 |
| Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects (NCT00499707) | GlaxoSmithKline | 2003-10-08 |
| Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol (NCT00549133) | Sanofi | 2003-10-01 |
| Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies. (NCT00069836) | GlaxoSmithKline | 2003-10-01 |
| Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement (NCT00354939) | Sanofi | 2003-10-01 |
| To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus. (NCT00419302) | Mannkind Corporation | 2003-10-01 |
| Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes (NCT00799448) | Novo Nordisk A/S | 2003-09-16 |
| Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus (NCT00085969) | AstraZeneca | 2003-09-01 |
| Determining the Effect on Patients of Internet-Based Diabetes Disease Management (NCT00220207) | Robert Wood Johnson Foundation | 2003-09-01 |
| Plant-Based Dietary Intervention in Type 2 Diabetes (NCT00276939) | Physicians Committee for Responsible Medicine | 2003-09-01 |
| Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes (NCT00612599) | Novo Nordisk A/S | 2003-09-01 |
| A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes (NCT00099957) | Novartis Pharmaceuticals | 2003-09-01 |
| MK0767 Added to Insulin Therapy in Patients With Type 2 Diabetes (0767-030) (NCT00543816) | Merck Sharp & Dohme LLC | 2003-08-01 |
| Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin (NCT00569998) | Novo Nordisk A/S | 2003-08-01 |
| Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes (NCT00617565) | Novo Nordisk A/S | 2003-07-08 |
| Improving Diabetes Outcomes With Activity, Nutrition and Medication (NCT00179374) | Albert Einstein College of Medicine | 2003-07-01 |
| Study of the Relationship Between Blood Vessels and Insulin Response in Adolescents (NCT00374361) | Ohio State University | 2003-07-01 |
| An Observational Study of Insulin Aspart and, if Necessary, Insulin Levemir (FlexPen®) in the Evening or at Bedtime (NCT01487421) | Novo Nordisk A/S | 2003-07-01 |
| Pilot Study of Vedic Medicine for Type 2 Diabetes (NCT00065650) | National Center for Complementary and Integrative Health (NCCIH) | 2003-07-01 |